California Public Employees Retirement System Reduces Position in STAAR Surgical (NASDAQ:STAA)

California Public Employees Retirement System lessened its holdings in shares of STAAR Surgical (NASDAQ:STAAGet Rating) by 15.6% in the 2nd quarter, Holdings Channel reports. The fund owned 84,627 shares of the medical instruments supplier’s stock after selling 15,592 shares during the quarter. California Public Employees Retirement System’s holdings in STAAR Surgical were worth $6,003,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Lazard Asset Management LLC grew its stake in STAAR Surgical by 131.1% during the 1st quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 388 shares in the last quarter. Covestor Ltd grew its stake in shares of STAAR Surgical by 162.6% in the 1st quarter. Covestor Ltd now owns 1,111 shares of the medical instruments supplier’s stock valued at $89,000 after buying an additional 688 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of STAAR Surgical by 18.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,287 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 202 shares during the period. Meeder Asset Management Inc. grew its stake in shares of STAAR Surgical by 815.0% in the 1st quarter. Meeder Asset Management Inc. now owns 1,345 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 1,198 shares during the period. Finally, Prospera Financial Services Inc purchased a new stake in shares of STAAR Surgical in the 1st quarter valued at approximately $118,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.

Insider Buying and Selling at STAAR Surgical

In related news, VP James E. Francese sold 35,425 shares of the business’s stock in a transaction that occurred on Tuesday, September 27th. The stock was sold at an average price of $75.00, for a total transaction of $2,656,875.00. Following the transaction, the vice president now directly owns 34,908 shares of the company’s stock, valued at approximately $2,618,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.60% of the company’s stock.

STAAR Surgical Price Performance

Shares of STAA stock opened at $61.04 on Friday. The stock has a market cap of $2.94 billion, a P/E ratio of 80.32 and a beta of 1.11. The stock has a fifty day moving average price of $69.29 and a 200 day moving average price of $74.73. STAAR Surgical has a one year low of $49.03 and a one year high of $112.27.

STAAR Surgical (NASDAQ:STAAGet Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The medical instruments supplier reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. STAAR Surgical had a return on equity of 15.13% and a net margin of 13.54%. The firm had revenue of $76.05 million during the quarter, compared to analyst estimates of $74.95 million. During the same period last year, the company earned $0.13 earnings per share. The company’s revenue was up 30.3% on a year-over-year basis. Equities research analysts anticipate that STAAR Surgical will post 0.75 EPS for the current year.

Analyst Upgrades and Downgrades

STAA has been the topic of a number of recent analyst reports. UBS Group dropped their price objective on shares of STAAR Surgical from $97.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, October 14th. Benchmark raised their price objective on shares of STAAR Surgical from $97.00 to $117.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. Canaccord Genuity Group lifted their target price on shares of STAAR Surgical from $89.00 to $97.00 in a research report on Thursday, August 11th. Mizuho began coverage on shares of STAAR Surgical in a research report on Wednesday, October 12th. They set a “buy” rating and a $85.00 target price for the company. Finally, Sidoti upgraded shares of STAAR Surgical from a “neutral” rating to a “buy” rating in a report on Monday, November 7th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.89.

STAAR Surgical Profile

(Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Stories

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAAGet Rating).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.